AP2011005979A0 - Pharmaceutical composition for a hepatitis C viralprotease inhibitor. - Google Patents

Pharmaceutical composition for a hepatitis C viralprotease inhibitor.

Info

Publication number
AP2011005979A0
AP2011005979A0 AP2011005979A AP2011005979A AP2011005979A0 AP 2011005979 A0 AP2011005979 A0 AP 2011005979A0 AP 2011005979 A AP2011005979 A AP 2011005979A AP 2011005979 A AP2011005979 A AP 2011005979A AP 2011005979 A0 AP2011005979 A0 AP 2011005979A0
Authority
AP
ARIPO
Prior art keywords
viralprotease
hepatitis
inhibitor
pharmaceutical composition
pharmaceutical
Prior art date
Application number
AP2011005979A
Other languages
English (en)
Inventor
Feng-Jing Chen
Robert J Schwabe
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AP2011005979A0 publication Critical patent/AP2011005979A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AP2011005979A 2009-07-07 2010-07-01 Pharmaceutical composition for a hepatitis C viralprotease inhibitor. AP2011005979A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22350709P 2009-07-07 2009-07-07
PCT/US2010/040734 WO2011005646A2 (en) 2009-07-07 2010-07-01 Pharmaceutical composition for a hepatitis c viral protease inhibitor

Publications (1)

Publication Number Publication Date
AP2011005979A0 true AP2011005979A0 (en) 2011-12-31

Family

ID=43245003

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005979A AP2011005979A0 (en) 2009-07-07 2010-07-01 Pharmaceutical composition for a hepatitis C viralprotease inhibitor.

Country Status (35)

Country Link
US (1) US9034831B2 (sr)
EP (1) EP2451438B8 (sr)
JP (1) JP5607736B2 (sr)
KR (1) KR101685941B1 (sr)
CN (1) CN102470103B (sr)
AP (1) AP2011005979A0 (sr)
AR (1) AR077393A1 (sr)
AU (1) AU2010270783B2 (sr)
BR (1) BR112012000287B8 (sr)
CA (1) CA2767692C (sr)
CL (1) CL2012000054A1 (sr)
CO (1) CO6480980A2 (sr)
DK (1) DK2451438T3 (sr)
EA (1) EA023433B1 (sr)
EC (1) ECSP12011624A (sr)
ES (1) ES2464367T3 (sr)
GE (1) GEP20146016B (sr)
HR (1) HRP20140445T1 (sr)
IL (1) IL216098A (sr)
MA (1) MA33491B1 (sr)
ME (1) ME01718B (sr)
MX (1) MX2011013824A (sr)
MY (1) MY154683A (sr)
NZ (1) NZ596928A (sr)
PE (1) PE20120322A1 (sr)
PL (1) PL2451438T3 (sr)
PT (1) PT2451438E (sr)
RS (1) RS53209B (sr)
SG (1) SG177569A1 (sr)
SI (1) SI2451438T1 (sr)
TN (1) TN2012000009A1 (sr)
TW (1) TWI490216B (sr)
UA (1) UA104195C2 (sr)
UY (1) UY32760A (sr)
WO (1) WO2011005646A2 (sr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2737376A1 (en) * 2008-09-17 2010-03-25 Boehringer Ingelheim International Gmbh Combination of hcv ns3 protease inhibitor with interferon and ribavirin
MY154683A (en) 2009-07-07 2015-07-15 Boehringer Ingelheim Int Pharmaceutical composition for a hepatitis c viral protease inhibitor
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
CA2813093A1 (en) 2010-09-30 2012-04-05 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
HK1204982A1 (en) * 2012-01-12 2015-12-11 勃林格殷格翰国际有限公司 Stabilized pharmaceutical formulations of a potent hcv inhibitor
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013147749A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient subgenotype populations
WO2013147750A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
JP2015512900A (ja) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のhcv感染症を治療するための併用療法
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company C型肝炎ウイルス阻害剤
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
CN105228593B (zh) * 2013-03-15 2018-08-28 勃林格殷格翰国际有限公司 呈无定形状态的hcv抑制剂的固体口服剂型
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
SG11202111742QA (en) 2019-04-24 2021-11-29 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
CA3142710A1 (en) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
PH12021552872A1 (en) 2020-04-05 2022-03-21 Pfizer Compounds and methods for the treatment of covid-19

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2907460A1 (de) 1978-03-07 1979-09-13 Sandoz Ag Neue resorbierbare galenische kompositionen
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
IL102236A0 (en) 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
US5329976A (en) 1991-12-09 1994-07-19 Habley Medical Technology Corporation Syringe-filling and medication mixing dispenser
GB9208712D0 (en) 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
ATE398448T1 (de) 1993-09-28 2008-07-15 Scherer Gmbh R P Herstellung von weichgelatinekapseln
JPH11505257A (ja) 1995-05-19 1999-05-18 アボツト・ラボラトリーズ 親油性薬物の自己乳化性製剤
US5993858A (en) 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
ATE265847T1 (de) * 1997-07-29 2004-05-15 Upjohn Co Selbstemulgierbare formulierung enthaltend lipophile verbindungen
PL192080B1 (pl) 1997-07-29 2006-08-31 Upjohn Co Kompozycja farmaceutyczna zawierająca związek piranonowy
HU228923B1 (en) 1997-07-29 2013-06-28 Upjohn Co Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6652880B1 (en) 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
US6710195B2 (en) 2001-11-26 2004-03-23 Supergen, Inc. Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
CZ294371B6 (cs) 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
US20040033959A1 (en) * 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
UY28240A1 (es) 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
EP1613353A1 (en) 2003-04-02 2006-01-11 Boehringer Ingelheim International GmbH Pharmaceutical compositions for hepatitis c viral protease inhibitors
CL2004001161A1 (es) * 2003-05-21 2005-04-08 Boehringer Ingelheim Int Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
ES2361997T3 (es) 2003-09-22 2011-06-27 Boehringer Ingelheim International Gmbh Péptidos macrocíclicos activos contra el virus de la hepatitis c.
RU2006136084A (ru) 2004-03-15 2008-04-27 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Способ получения микроциклических соединений
AP2006003763A0 (en) 2004-03-30 2006-10-31 Intermune Inc Macrocyclic compounds as inhibitors of viral replication
CA2568008C (en) 2004-05-25 2014-01-28 Boehringer Ingelheim International Gmbh Process for preparing acyclic hcv protease inhibitors
WO2006130552A2 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
RU2490272C2 (ru) 2008-02-04 2013-08-20 Айденикс Фармасьютикалз, Инк. Макроциклические ингибиторы серинпротеазы
PE20130307A1 (es) 2008-09-16 2013-03-22 Boehringer Ingelheim Int Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv
KR20110087297A (ko) 2008-11-21 2011-08-02 베링거 인겔하임 인터내셔날 게엠베하 경구 투여용의 강력한 hcv 억제제의 약제학적 조성물
MY154683A (en) 2009-07-07 2015-07-15 Boehringer Ingelheim Int Pharmaceutical composition for a hepatitis c viral protease inhibitor

Also Published As

Publication number Publication date
SI2451438T1 (sl) 2014-04-30
AU2010270783B2 (en) 2013-06-27
EP2451438B1 (en) 2014-02-26
PL2451438T3 (pl) 2014-07-31
CN102470103A (zh) 2012-05-23
ES2464367T3 (es) 2014-06-02
JP5607736B2 (ja) 2014-10-15
BR112012000287B1 (pt) 2020-12-08
WO2011005646A3 (en) 2011-12-22
ME01718B (me) 2014-09-20
MY154683A (en) 2015-07-15
TWI490216B (zh) 2015-07-01
PT2451438E (pt) 2014-03-26
HRP20140445T1 (hr) 2014-06-20
CA2767692A1 (en) 2011-01-13
EA201200096A1 (ru) 2012-08-30
SG177569A1 (en) 2012-03-29
JP2012532192A (ja) 2012-12-13
IL216098A0 (en) 2012-01-31
EP2451438A2 (en) 2012-05-16
DK2451438T3 (da) 2014-03-10
WO2011005646A2 (en) 2011-01-13
AR077393A1 (es) 2011-08-24
UA104195C2 (ru) 2014-01-10
US9034831B2 (en) 2015-05-19
CL2012000054A1 (es) 2012-10-12
GEP20146016B (en) 2014-01-27
MX2011013824A (es) 2012-01-30
PE20120322A1 (es) 2012-04-14
AU2010270783A1 (en) 2011-12-15
NZ596928A (en) 2013-05-31
ECSP12011624A (es) 2012-02-29
RS53209B (sr) 2014-06-30
KR20120059481A (ko) 2012-06-08
IL216098A (en) 2016-02-29
UY32760A (es) 2011-02-28
TN2012000009A1 (en) 2013-09-19
CO6480980A2 (es) 2012-07-16
US20110160149A1 (en) 2011-06-30
CA2767692C (en) 2017-03-07
KR101685941B1 (ko) 2016-12-13
BR112012000287A2 (pt) 2016-02-23
EA023433B1 (ru) 2016-06-30
MA33491B1 (fr) 2012-08-01
TW201114766A (en) 2011-05-01
CN102470103B (zh) 2016-09-07
EP2451438B8 (en) 2014-04-09
BR112012000287B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
AP2011005979A0 (en) Pharmaceutical composition for a hepatitis C viralprotease inhibitor.
ZA201104336B (en) Pharmaceutical compounds
IL216256A0 (en) A pharmaceutical composition
GB0816372D0 (en) Pharmaceutical compounds
GB0820819D0 (en) Pharmaceutical compounds
GB0801416D0 (en) Pharmaceutical compounds
PL2285413T3 (pl) Kompozycja farmaceutyczna
EP2504343A4 (en) HEPATITIS C INHIBITOR COMPOUNDS
GB0816371D0 (en) Pharmaceutical compounds
EP2344487A4 (en) HEPATITIS C INHIBITOR COMPOUNDS
GB0812969D0 (en) Pharmaceutical compounds
SI2271618T1 (sl) Farmacevtske spojine
GB0816370D0 (en) Pharmaceutical compounds
GB0712389D0 (en) A Pharmaceutical composition
GB0922589D0 (en) Pharmaceutical compounds
GB0810857D0 (en) Pharmaceutical compounds
SI2389164T1 (sl) Farmacevtski sestavki, obsegajoäśi predzdravilo inhibitorja hcv polimeraze
GB2480585B (en) A tablet composition
PL2309992T3 (pl) Kompozycja farmaceutyczna zawierająca statynę
GB0908905D0 (en) Pharmaceutical compounds
GB0917775D0 (en) Novel pharmaceutical compounds
GB0917774D0 (en) Novel pharmaceutical compounds
AU2009100050A4 (en) Fork Tie Down Brackets
GB0917677D0 (en) Pharmaceutical compounds
GB0915125D0 (en) Pharmaceutical compounds